NCT00376285撤回1 期
A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Pfizer
- 主要终点
- Toleration and safety
研究概览
简要总结
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •BMI of 30-40 kg/m2
排除标准
- •Women of childbearing potential
结局指标
主要结局
Toleration and safety
次要结局
- Efficacy biomarkers, serum lipids
研究者
相似试验
已完成
2 期
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's DiseaseHuntington DiseaseNCT03515213University of California, Irvine10
已完成
2 期
A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 DiabetesPatients With Type 2 DiabetesNCT00703482Solvay Pharmaceuticals278
进行中（未招募）
3 期
Fenofibrate for Prevention of DR WorseningDiabetic RetinopathyNCT04661358Jaeb Center for Health Research563
终止
2 期
Effect of Fenofibrate on Sleep Apnea SyndromeOverweightObesityDyslipidemiaSleep Apnea SyndromeNCT00816829Solvay Pharmaceuticals34
进行中（未招募）
3 期
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.Diabetic NephropathiesType 1 Diabetes MellitusDiabetic RetinopathyNCT01320345University of Sydney412